HOME View All Genre

Book

Audiobook

GENRES 🌙 Dark

Genome-Based Diagnostics - Steve Olson, Roundtable on Translating Genomic-Based Research for Health, Board on Health Sciences Policy & Institute of Medicine

By Steve Olson, Roundtable on Translating Genomic-Based Research for Health, Board on Health Sciences Policy & Institute of Medicine

Release Date: 2012-06-27

Genre: Medical

(0 ratings)
Read Download
The sequencing of the human genome and the identification of associations between specific genetic variants and diseases have led to an explosion of genomic-based diagnostic tests. These tests have the potential to direct therapeutic interventions, predict risk or onset of disease, or detect residual disease. As research progresses and an increasing number of associations are found, further tests will be developed that can aid in providing personalized treatment options for patients. However, the adoption of genomic diagnostic tests by health care providers has been limited due to a lack of evidence regarding the clinical utility of many tests.  Health funders and practitioners lack the data necessary to distinguish which tests can improve practice or the clinical settings in which tests will provide the greatest value. The Roundtable on Translating Genomic-Based Research for Health held a workshop in November 2010 to determine what evidence is needed and how it is viewed by different stakeholders in order to develop genomic diagnostic tests of clinical value.

Genome-Based Diagnostics summarizes the presentations and discussions that took place throughout the workshop. Two presentations, in particular, sparked extensive discussion. One presentation proposed that all genomic diagnostic tests be reviewed and approved by the Food and Drug Administration. The other observed that venture capitalists are no longer investing substantially in the development of genomic diagnostic tests because of a lack of clarity surrounding regulatory and reimbursement pathways. Both presentations suggested the need for major changes in the systems used to develop, regulate, and reimburse genomic diagnostic tests. The report also presents the perspectives of different stakeholders in the development of genomic diagnostic tests. Each stakeholder group has a different set of needs and issues of importance, yet commonalities among them are apparent, such as the need to put patients and health outcomes at the center of discussion and action.

Genome-Based Diagnostics - Steve Olson, Roundtable on Translating Genomic-Based Research for Health, Board on Health Sciences Policy & Institute of Medicine

By Steve Olson, Roundtable on Translating Genomic-Based Research for Health, Board on Health Sciences Policy & Institute of Medicine

Release Date: 2012-06-27

Genre: Medical

(0 ratings)
Read Download
The sequencing of the human genome and the identification of associations between specific genetic variants and diseases have led to an explosion of genomic-based diagnostic tests. These tests have the potential to direct therapeutic interventions, predict risk or onset of disease, or detect residual disease. As research progresses and an increasing number of associations are found, further tests will be developed that can aid in providing personalized treatment options for patients. However, the adoption of genomic diagnostic tests by health care providers has been limited due to a lack of evidence regarding the clinical utility of many tests.  Health funders and practitioners lack the data necessary to distinguish which tests can improve practice or the clinical settings in which tests will provide the greatest value. The Roundtable on Translating Genomic-Based Research for Health held a workshop in November 2010 to determine what evidence is needed and how it is viewed by different stakeholders in order to develop genomic diagnostic tests of clinical value.

Genome-Based Diagnostics summarizes the presentations and discussions that took place throughout the workshop. Two presentations, in particular, sparked extensive discussion. One presentation proposed that all genomic diagnostic tests be reviewed and approved by the Food and Drug Administration. The other observed that venture capitalists are no longer investing substantially in the development of genomic diagnostic tests because of a lack of clarity surrounding regulatory and reimbursement pathways. Both presentations suggested the need for major changes in the systems used to develop, regulate, and reimburse genomic diagnostic tests. The report also presents the perspectives of different stakeholders in the development of genomic diagnostic tests. Each stakeholder group has a different set of needs and issues of importance, yet commonalities among them are apparent, such as the need to put patients and health outcomes at the center of discussion and action.

More by Steve Olson, Roundtable on Translating Genomic-Based Research for Health, Board on Health Sciences Policy & Institute of Medicine

Eruption

The Apocalypse Factory

Anarchy Evolution

From Neurons to Neighborhoods

Evolution in Hawaii

Inquiry and the National Science Education Standards

Strengthening High School Chemistry Education Through Teacher Outreach Programs

The Past Half Century of Engineering---And a Look Forward

Considerations in Applying Benefit-Cost Analysis to Preventive Interventions for Children, Youth, and Families:

Trends in the Innovation Ecosystem

Genome-Based Diagnostics

Making Things

Educating Engineers: Preparing 21st Century Leaders in the Context of New Modes of Learning

Accelerating the Development of New Drugs and Diagnostics

Nurturing and Sustaining Effective Programs in Science Education for Grades K-8

Cross-Sector Responses to Obesity

Using Existing Platforms to Integrate and Coordinate Investments for Children

Fostering Independence, Participation, and Healthy Aging Through Technology

Exploring Opportunities for STEM Teacher Leadership

Rebuilding a Real Economy

Sharing Clinical Research Data:

Protecting National Park Soundscapes

Opportunities to Promote Children's Behavioral Health

Evaluation Design for Complex Global Initiatives

Strengthening a Workforce for Innovative Regulatory Science in Therapeutics Development

Beyond Experience: The Path from Doing to Knowing to Wisdom

The Role of Human Factors in Home Health Care

The Global Crisis of Drug-Resistant Tuberculosis and Leadership of China and the BRICS

The Emerging Threat of Drug-Resistant Tuberculosis in Southern Africa

Measuring the Impacts of Federal Investments in Research

Establishing Precompetitive Collaborations to Stimulate Genomics-Driven Drug Development

Facing the Reality of Drug-Resistant Tuberculosis

Innovations in Design and Utilization of Measurement Systems to Promote Children's Cognitive, Affective, and Behavioral Health

The Current State of Obesity Solutions in the United States

Nutrition Education in the K-12 Curriculum

Increasing National Resilience to Hazards and Disasters

Allied Health Workforce and Services

Global Technology

Thinking Evolutionarily

The Importance of Engineering Talent to the Prosperity and Security of the Nation

The New Profile of Drug-Resistant Tuberculosis in Russia:

Accelerating the Development of Biomarkers for Drug Safety

Integrating Large-Scale Genomic Information into Clinical Practice

Challenges and Opportunities in Using Residual Newborn Screening Samples for Translational Research

Sensing and Shaping Emerging Conflicts

STEM Learning Is Everywhere

Toward an Integrated Science of Research on Families

State Science and Technology Policy Advice:

Related Articles